This is a StreetInsider.com Premium Only Page

Pieris Pharma (PIRS) –

Apr 18, 2024 04:24 PM Pieris Pharma (PIRS) Approves 1:80 Share Buyback

Apr 18, 2024 04:22 PM Form 8-K PIERIS PHARMACEUTICALS, For: Apr 18

Mar 29, 2024 05:32 PM Form 10-K PIERIS PHARMACEUTICALS, For: Dec 31

Mar 27, 2024 08:03 AM Pieris Pharma (PIRS) Announces Strategy to Maximize Partnered Milestone and Royalty Potential

Mar 27, 2024 08:00 AM Form 8-K PIERIS PHARMACEUTICALS, For: Mar 27

Mar 27, 2024 08:00 AM Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

Feb 14, 2024 04:38 PM Form SC 13G/A PIERIS PHARMACEUTICALS, Filed by: Aquilo Capital Management, LLC

Feb 14, 2024 01:12 PM Form SC 13G/A PIERIS PHARMACEUTICALS, Filed by: Checkpoint Capital L.P.

Feb 14, 2024 09:20 AM Form SC 13G/A PIERIS PHARMACEUTICALS, Filed by: Lynx1 Capital Management LP

Feb 2, 2024 10:00 AM Form SC 13G/A PIERIS PHARMACEUTICALS, Filed by: Soleus Capital Master Fund, L.P.

Dec 21, 2023 04:30 PM Form 8-K PIERIS PHARMACEUTICALS, For: Dec 15

Nov 14, 2023 04:22 PM Form 10-Q PIERIS PHARMACEUTICALS, For: Sep 30

Aug 31, 2023 04:16 PM Form 8-K/A PIERIS PHARMACEUTICALS, For: Jul 17

Aug 17, 2023 04:50 PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: BIOTECHNOLOGY VALUE FUND L P

Aug 17, 2023 08:03 AM Pieris Pharma (PIRS) Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342

Aug 17, 2023 08:00 AM Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Aug 10, 2023 05:05 PM Form S-8 PIERIS PHARMACEUTICALS,

Aug 10, 2023 04:25 PM Form 10-Q PIERIS PHARMACEUTICALS, For: Jun 30

Jul 18, 2023 09:16 AM Pieris Pharma (PIRS) Provides Strategic Update and Announces Restructuring

Jul 18, 2023 09:15 AM Form 8-K PIERIS PHARMACEUTICALS, For: Jul 17

Jul 18, 2023 09:15 AM Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

Jul 18, 2023 09:10 AM Pieris Pharma (PIRS) Halted, News Pending

Jul 13, 2023 07:31 AM Form 8-K PIERIS PHARMACEUTICALS, For: Jul 13

Jun 26, 2023 05:25 PM Form 8-K PIERIS PHARMACEUTICALS, For: Jun 21

Jun 23, 2023 04:47 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: Barbier Ann

Jun 23, 2023 04:47 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: Kiener Peter A

Jun 23, 2023 04:47 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: GERAGHTY JAMES A

Jun 23, 2023 04:47 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: KIRITSY CHRISTOPHER P

Jun 23, 2023 04:46 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: Richman Michael

Jun 23, 2023 04:46 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: Sherman Matthew L

Jun 23, 2023 04:46 PM Form 4 PIERIS PHARMACEUTICALS, For: Jun 21 Filed by: Said Maya R.

Jun 21, 2023 07:09 AM Pieris Pharma (PIRS) to Resume Trading at 7:30 a.m.

Jun 21, 2023 07:03 AM Pieris Pharma (PIRS) Announces AstraZeneca's (AZN) Discontinuation of Phase 2a Trial of Elarekibep

Jun 21, 2023 07:01 AM Form 8-K PIERIS PHARMACEUTICALS, For: Jun 21

Jun 21, 2023 07:00 AM Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

Jun 21, 2023 06:55 AM Pieris Pharma (PIRS) Halted, News Pending

Jun 12, 2023 06:43 AM Form SC 13G PIERIS PHARMACEUTICALS, Filed by: Checkpoint Capital L.P.

Jun 8, 2023 06:02 AM Form 8-K PIERIS PHARMACEUTICALS, For: Jun 08

Jun 2, 2023 04:30 PM Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

May 30, 2023 04:21 PM Form 4 PIERIS PHARMACEUTICALS, For: May 25 Filed by: KIRITSY CHRISTOPHER P

May 22, 2023 05:01 PM Form 3 PIERIS PHARMACEUTICALS, For: May 11 Filed by: BVF I GP LLC

May 22, 2023 04:47 PM Form SC 13D PIERIS PHARMACEUTICALS, Filed by: BIOTECHNOLOGY VALUE FUND L P

May 22, 2023 08:00 AM Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

May 21, 2023 08:00 AM Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

May 19, 2023 04:06 PM Form 8-K PIERIS PHARMACEUTICALS, For: May 15

May 11, 2023 06:02 AM Form 10-Q PIERIS PHARMACEUTICALS, For: Mar 31

May 10, 2023 07:31 AM Form 8-K PIERIS PHARMACEUTICALS, For: May 10

May 10, 2023 07:00 AM Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

May 4, 2023 08:02 AM Pieris Pharma (PIRS) Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep

May 4, 2023 08:00 AM Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)